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Consortium*, Naomi R. Wray  3,4 & Sang Hong Lee1,2,4
Previous studies have shown an increased risk for mental health problems in children born to both 
younger and older parents compared to children of average-aged parents. We previously used a novel 
design to reveal a latent mechanism of genetic association between schizophrenia and age at first 
birth in women (AFB). Here, we use independent data from the UK Biobank (N = 38,892) to replicate 
the finding of an association between predicted genetic risk of schizophrenia and AFB in women, and 
to estimate the genetic correlation between schizophrenia and AFB in women stratified into younger 
and older groups. We find evidence for an association between predicted genetic risk of schizophrenia 
and AFB in women (P-value = 1.12E-05), and we show genetic heterogeneity between younger and 
older AFB groups (P-value = 3.45E-03). The genetic correlation between schizophrenia and AFB in 
the younger AFB group is −0.16 (SE = 0.04) while that between schizophrenia and AFB in the older 
AFB group is 0.14 (SE = 0.08). Our results suggest that early, and perhaps also late, age at first birth 
in women is associated with increased genetic risk for schizophrenia in the UK Biobank sample. These 
findings contribute new insights into factors contributing to the complex bio-social risk architecture 
underpinning the association between parental age and offspring mental health.
An increased risk for a range of mental health issues in children born to both younger and older parents com-
pared to children of average-aged parents has been reported in many studies1–8, with a particular focus on the risk 
of schizophrenia (SCZ) in children associated with parental age9–12. A recent comprehensive analysis using family 
data extracted from the Danish Psychiatric Central Register reported a relationship between mother’s age and 
risk of SCZ in her offspring13. They showed that there was higher risk in children of younger and older mothers 
compared to those of intermediate age (25–29 years – i.e. a U-shaped relationship between maternal age and risk 
of SCZ in offspring), but it was unclear if this was due to psychosocial factors associated with maternal age or if 
mothers at higher genetic risk for SCZ tend to have children at an earlier or later age. Moreover, the very high 
correlation in spousal ages makes paternal and maternal contributions to this relationship difficult to disentan-
gle. A number of possible latent mechanisms behind these epidemiological observations have been proposed14, 
including shared genetic risk factors between parents and offspring15,16 (Fig. 1). A better understanding of factors 
contributing to the relationship between parental age and risk of psychiatric disorders is important for informing 
any future public health initiatives targeting this relationship.
We have previously reported evidence for a genetic relationship between maternal age at first birth (AFB) 
and risk of SCZ17, as illustrated in red in Fig. 1. We employed a novel design that directly tests the genetic risk 
of SCZ in mothers depending on AFB. In all previous study designs the psychiatric disorder was measured in 
the child, and hence the relationship with AFB in the mother was confounded with characteristics of the father. 
Here, and in our previous study we examine the relationship between SCZ and AFB by using a genetic predictor 
of SCZ in the mother. The analyses use community samples of women enrolled in research studies that were not 
enriched for psychiatric disorders (<1% for diagnosis with SCZ). The genetic predictor for SCZ can be calculated 
for all women in the studies as a function (such as weighted sum) of the SCZ risk alleles they carry, with the risk 
1Australian Center for Precision Health, University of South Australia Cancer Research Institute, University of 
South Australia, Adelaide, SA, 5000, Australia. 2School of Environmental and Rural Science, University of New 
England, Armidale, NSW, 2351, Australia. 3Institute for Molecular Bioscience, University of Queensland, Brisbane, 
Queensland, 4072, Australia. 4Queensland Brain Institute, University of Queensland, Brisbane, Queensland, 4072, 
Australia. *A comprehensive list of consortium members appears at the end of the paper. Correspondence and 
requests for materials should be addressed to S.H.L. (email: hong.lee@unisa.edu.au)
Received: 8 December 2017
Accepted: 14 June 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
alleles identified as having increased frequencies in SCZ cases compared to controls. A woman’s genetic risk for 
schizophrenia is solely a function of her DNA, which she received independently of the characteristics of her 
partner. Hence, a benefit of this novel design is that the inferred association is not confounded by artefactual or 
non-genetic association(s) such as increased SCZ risk in offspring due to maternal environmental effects or by 
confounding with father’s age. We showed that the U-shaped relationship (between maternal age at birth and SCZ 
risk in offspring) observed in epidemiological studies was also observed when considering predicted genetic risk 
for SCZ as a function of AFB in healthy women13,17.
In this study, we replicate and extend our earlier findings17 using the UK Biobank data in which community 
samples of women have been measured for AFB. First, we confirm that SCZ polygenic risk score (PRS) for women 
in the UK Biobank with a record of AFB (N = 38,892) significantly predicts the U-shaped relationship found in 
McGrath et al.13, thereby replicating the results in Mehta et al.17. Second, we test if there is a genetic heterogeneity 
for AFB between younger and older AFB groups. Third, we estimate the genetic correlation between SCZ and 
AFB in younger and older AFB groups.
Results
Overview. In total, 41,630 SCZ GWAS samples including 18,957 cases and 22,673 controls from 30 cohorts 
were used in this study (Table S1), which were the same data used in Mehta et al.17. For the UK Biobank sample, 
38,892 women were used. The distribution of AFB, age at interview, and year of birth for the UK Biobank data 
after QC are shown in Fig. S1. In total, 518,992 SNPs passed the quality control criteria and were in common 
across the SCZ and UK Biobank samples. The distribution of MAF is shown in Fig. S2. Figure S3 shows that there 
were no closely related individuals in the UK Biobank and SCZ case-control data sets, confirming that the two 
data sets were independent.
We estimated SCZ PRS for each individual in the UK Biobank sample, using the SCZ GWAS as a reference 
data set (see Methods). We used both the genetic profile score approach18 (PRS-score) and genomic best linear 
unbiased prediction method (PRS-GBLUP). We assessed the U-shaped relationship between AFB and SCZ PRS 
for the UK Biobank sample. We emphasize that in this novel design, it was not necessary to measure SCZ risk in 
offspring, and in our strategy potential confounding due to a correlation between paternal and maternal age was 
mostly removed.
Subsequently, we estimated SNP-heritability and genetic correlation between AFB and SCZ. Because of the 
non-linear relationship (U-shape), we divided the UK Biobank sample into two groups with younger and older 
AFB. We assessed if the younger and older AFB groups were genetically heterogeneous, and if there is any signif-
icant genetic correlation between SCZ and each of the younger and older AFB groups.
Relationship between SCZ PRS and AFB. Consistent with McGrath et al.13 and replicating the findings 
in Mehta et al.17, a U-shaped relationship was observed between AFB and SCZ PRS-GBLUP (Fig. 2 and Table S2), 
implying genetic pleiotropic effects on AFB and SCZ risk. Figure 2 shows the mean and standard error of SCZ 
PRS-GBLUP in the UK Biobank sample grouped by AFB. The mean SCZ PRS-GBLUP in women with early AFB 
(<20 years) was significantly higher than that in women with intermediate AFB (P-value = 2.2E-02 for AFB 
between 20 to <25 years, P-value = 1.2E-05 for AFB between 25 to <30 years, P-value = 2.0E-02 for AFB between 
30 to <35 years, in Table S3), but not in women with high AFB (P-value = 4.9E-01 for AFB ≥ 35 years). The mean 
SCZ PRS-GBLUP in women with AFB between 25 to <30 years was significantly lower than that in women with 
AFB between 20 to <25 years (P-value = 2.0E-03). Our results confirmed the findings in Mehta et al.17, i.e. a 
U-shaped relationship between AFB and SCZ PRS attributed to latent genetic factors, with stronger significance. 
The results were similar whether PRS was calculated using GBLUP (PRS-GBLUP) or conventional profile scoring 
based on GWAS summary statistics from the SCZ GWAS data (PRS-score) (Fig. S4 and Table S3). We also con-
firmed that the U-shaped relationship was replicated with estimated SNP effects from the full PGC SCZ GWAS 
Figure 1. A flowchart of suggested mechanisms contributing to the relationship between the parental age and 
the schizophrenia risk in offspring.
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study (PRS-scorePGC) (See Fig. S4 and Table S4), although these results could be biased due to possible sample 
overlap or the presence of relatives between the UK Biobank and the full PGC SCZ data.
Linear predictor. Following Mehta et al.17, we tested if SCZ PRS could predict the response variable (see 
Methods) that described the relationship between SCZ risk in offspring and maternal age derived in McGrath et al.13. 
Figure 3 shows that the response variable was significantly predicted by SCZ PRS for the group with the full range 
of AFB (P-value = 1.12E-05 for PRS-GBLUP, and P-value = 3.53E-07 for PRS-score and P-value = 3.08E-06 for 
PRS-scorePGC) and the subgroup with AFB younger than 26 (P-value = 4.71E-06, 6.06E-08 and 2.45E-06 for 
PRS-GBLUP, PRS-score and PRS-scorePGC, respectively), but not for the subgroup with AFB older than 26. 
The prediction with PRS-score was stronger than that with PRS-scorePGC, and both stronger than that with 
PRS-GBLUP although the results across the methods were not substantially different (Fig. 3).
Education level, income level, smoking and alcohol drinker status were additionally used to adjust the 
response variable in the linear prediction to test if those factors diminish the signals. Even with this conservative 
model, our results for the group with full range of AFB and the subgroup with AFB younger than 26 remained 
significant (Fig. S5 and Table S5), albeit with reduced effect size and significance. The reduced significance might 
be partly explained by the reduced sample size (i.e. for full range of AFB, N = 38,892 in the base model and 31,848 
Figure 2. Mean and standard error of schizophrenia polygenic risk scores estimated from Genomic Best Linear 
Unbiased Prediction (GBLUP) in the UK Biobank sample grouped by age at first birth.
Figure 3. −log(P) values for the null hypothesis of R2 = 0 based on the linear prediction. Full range of AFB: 
All available samples with a record of age at first birth were used. AFB < 26 (≥26): Analyses were only focus 
on samples with AFB < 26 (≥26). PRS-GBLUP: Schizophrenia (SCZ) polygenic risk scores estimated from 
genomic best linear unbiased prediction were used as an explanatory variable in the model. PRS-score: SCZ 
polygenic risk scores estimated from genome-wide association study based on available individual genotype 
data were used as an explanatory variable in the model. PRS-scorePGC: SCZ polygenic risk scores estimated 
from summary statistics results of full PGC SCZ GWAS study were used as an explanatory variable in the 
model. Response variables were generated with a polynomial function derived by Mehta et al.17, which describes 
the relationship between SCZ risk in offspring and maternal age (z = 2.7214 − 0.1105X + 0.0018X2, where X is 
age at first birth), and used in the model in which the AFB phenotypes were adjusted for age at interview, year of 
birth, assessment center at which participant consented, genotype batch, and the first 20 principal components.
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in model adjusted for education and income; see Table S5). In sensitivity analyses we also restricted the sample to 
those recruited at age ≥45 years (N = 35,451), which included the vast majority of women with a record of AFB, 
so that results were not biased by the exclusion of women with no reported AFB measure. We found that there 
was no substantive difference in our results despite the reduced sample size (Table S5 vs. S6).
The UK Biobank sample was divided into two subgroups born before or after 1945, a boundary of post-
ponement of AFB based on the theory of the second democratic transition19. For individuals born after 1945, 
PRS-GBLUP significantly predicted the response variable for the group with the full range of AFB and the sub-
group with AFB younger than 26, even after adjusting for socioeconomic status, and smoking and alcohol drinker 
status, but not for the subgroup with older AFB. For individuals born before 1945, PRS-GBLUP did not sig-
nificantly predict the response variable for the group with the full range of AFB (P-value = 6.52E-02) nor the 
subgroup with AFB younger or older than 26 (P-value = 4.99E-02 or 4.38E-01) (Table S7). Our results agreed 
with the results of Mehta et al.17 in that SCZ PRS of women significantly predicted the response variable for the 
group with the full range of AFB and the subgroup with AFB younger than 26. The signals became stronger for 
the individuals born after year 1945.
Genetic correlation between AFB and SCZ. Given that the AFB for women in the UK Biobank data was 
significantly predicted by PRS-GBLUP (P-value = 1.12E-05 and R2 = 4.96E-04 in Table S5), it was of interest to 
estimate the genetic correlation between AFB and SCZ, which is the scaled proportion of variance that AFB and 
SCZ share due to genetic factors.
The SNP-heritability was 0.03 (SE = 0.01), 0.10 (SE = 0.01), and 0.20 (SE = 0.004), for older AFB, younger 
AFB, and SCZ, respectively. The SNP-heritability for the older AFB group was not significantly different from 0 
(Fig. 4 right panel).
The estimated genetic correlation between younger and older AFB groups was significantly less than 1 
(rg = 0.47, SE = 0.19, P-value = 3.45E-03, in Table S8), indicating that younger and older AFB were genetically 
heterogeneous in the UK Biobank (Fig. 4 left panel). We demonstrate that a truncated selection had little impact 
on the estimation of the genetic correlation20 (Supplemental Notes 1 and 2 and Figs S6 and S7). Further, the 
estimated genetic correlation between SCZ and AFB in the younger AFB group was −0.16 (SE = 0.04) and that 
between SCZ and AFB in the older AFB group was 0.14 (SE = 0.08) (Fig. 4 left panel).
In sensitivity analyses, education level, income level, smoking and alcohol drinker status were additionally 
used to adjust the phenotypes in the genomic residual maximum likelihood (GREML) analyses to see if those fac-
tors change the estimates. Figure S8 shows that the estimates and their significance were slightly reduced, which 
could be partly explained by the decrease of sample size (N = 38,892 in the base model versus 31,848 in the model 
adjusted for education and income; see Table S8).
In addition to GREML, linkage disequilibrium score regression (LDSC)4,21 was applied to estimate the genetic 
correlation between SCZ and younger and older AFB (Table S9). As recommended by the LDSC papers4,21, 
pre-estimated LD scores from the 1000 Genome reference sample without constraining the intercept of regres-
sion were applied to the QCed GWAS data and full PGC SCZ GWAS summary results. However, we could access 
individual genotype data and it was clearly known that there was no overlapping sample and no high relatedness 
in the QCed GWAS data for which we would be able to use LD scores estimated based on the actual genotype 
Figure 4. Genetic correlation (left) and heritability (right) of age at first birth (AFB) ≥ 26, AFB < 26, and 
schizophrenia (SCZ). Cor(AFB < 26, AFB ≥ 26): Estimated genetic correlation between the groups with 
AFB < 26 and with AFB ≥ 26. Cor(SCZ, AFB ≥ 26): Estimated genetic correlation between SCZ and AFB in the 
older AFB group. Cor(SCZ, AFB < 26): Estimated genetic correlation between SCZ and AFB in the younger 
AFB group. The bars are standard errors. In the model, the AFB phenotypes were adjusted for age at interview, 
year of birth, assessment center at which participant consented, genotype batch and the first 20 principal 
components. And the SCZ phenotypes were adjusted for sex, cohorts and the first 20 principal components. The 
sample size for group AFB ≥ 26 was 17,598 and for group AFB < 26 was 21,294, and for group SCZ was 41,630.
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data as well as to constrain the intercept as zero. As reported4,21, it was observed from simulations (Supplemental 
Note 3) that if there was no overlapping sample, LDSC with constraining the intercept as zero gave the most accu-
rate estimate with the least standard error (Fig. S9). In the real data analyses, Table S9 showed that LDSC with 
constraining the intercept as zero gave similar estimates and standard errors, compared to those from GREML 
when using the QCed data. When explicitly estimating the intercept, the standard errors became large; therefore 
the precision of estimates might be decreased (Table S9). When using the full PGC SCZ GWAS summary, LDSC 
gave similar estimates but larger standard errors, compared to GREML estimates, although a larger SCZ sample 
size was used for LDSC analyses (77,096 for LDSC vs. 41,630 for GREML).
Discussion
Parental age has been consistently associated with an increased risk of SCZ in offspring9–13,15,16,22,23, but it is well 
known that traditional epidemiological study designs, based on data measured for parental age and SCZ status 
in their offspring, have limitations with respect to disentangling genetic effects from non-genetic confounding 
effects such as common and residual environmental effects (Fig. 1). The elevated risk of SCZ associated with 
parental age extends to children of both younger and older parents, compared to children of average aged par-
ents – i.e. a U-shaped relationship13. The most widely accepted mechanism, in the case of delayed parenthood, 
is a causal relationship due to the accumulation of de novo mutations with age (e.g. Kong et al.24), although this 
cannot explain increased risk in offspring of younger parents. This hypothesis is biologically plausible25–28, but 
Gratten et al.29 have shown using theory and simulations that paternal age-related de novo mutations are unlikely 
to be the major causal factor responsible for increased risk of SCZ in offspring. Instead, they argued that increased 
risk of SCZ in offspring of older fathers could be due to genetic overlap between risk of SCZ and delayed parent-
hood. This finding is consistent with epidemiological studies showing that paternal age at first child, as opposed 
to paternal age at conception, accounts for the increased risk of SCZ in the children of older fathers (i.e. arguing 
against a direct causal role for age-related de novo mutations)15,16. Notably, this mechanism of genetic overlap 
between parental age and SCZ applies equally well to offspring SCZ risk associated with early parenthood.
Recently, Mehta et al.17 used a novel design to investigate the genetic relationship between SCZ and AFB in 
women that is free of many of the potential confounders present in epidemiological study designs (e.g. poor 
maternity skill, psychosocial factors and shared environmental factors). Specifically, they used SNP effects 
obtained using SCZ case-control data to estimate genetic risk of SCZ in a general community sample of women 
measured for AFB. As expected, psychiatric disorder including SCZ was not enriched in this community sample 
(i.e. a general population). Therefore, there is hardly phenotypic assortative mating for the psychiatric disorder 
in the sample. In addition, the analyses were restricted to individuals with pairwise genomic relationship <0.05 
across samples to make sure that SCZ GWAS and AFB samples were independent. Thus, it was unlikely that they 
shared the common environmental factors. In this analysis, we used the novel design and replicated the finding 
in a much larger and independent community sample, the UK Biobank study. We confirmed the U-shaped rela-
tionship between AFB and SCZ PRS reported by Mehta et al.17 (Figs 2 and 3), and provided evidence of genetic 
overlap between SCZ and AFB in women. The large number of samples in the UK Biobank made it possible to 
also estimate genetic variance and covariance between SCZ and AFB using a linear mixed model, showing that 
the traits of younger and older AFB are genetically heterogeneous (Fig. 4 or Table S8). The genetic correlation 
between SCZ and AFB in women with AFB < 26 was −0.16 (SE = 0.04), which was significantly different from 
zero (Fig. 4). The genetic correlation between SCZ and AFB in women with AFB ≥ 26 was 0.14 (SE = 0.08), which 
was significantly larger, albeit by a marginal amount, than zero in a one-tail Wald test (p-value = 0.04). This shows 
that there is at least a suggestive signal for the genetic correlation between older AFB and SCZ, hence we cannot 
totally rule out the possibility of the association.
In linear prediction, results from PRS-score were similar to or more significant than those from PRS-scorePGC 
(Table S5). This is noteworthy because PRS-scorePGC was based on the GWAS summary statistics from the full 
PGC SCZ GWAS (33,640 cases, 43,456 controls, from 52 cohorts), which is a larger sample than that used to 
generate PRS-score (individual-level genotype data on 18,957 cases, 22,673 controls, from 30 cohorts). However, 
publicly available GWAS summary statistics such as those used for PRS-scorePGC provide incomplete informa-
tion about sample overlap or pairwise relationships between data sets, either of which could introduce biases or 
influence statistical significance due to non-independence of samples. There is an approach or strategy for related-
ness QC without accessing individual genotypes30, however, it is not immediately applicable to the full PGC SCZ 
data. We hypothesize that the superior performance of PRS-score in our analysis, despite smaller sample size than 
PRS-scorePGC (which is explained by restrictions on data access for individual-level genotype data), reflects the 
very stringent QC we applied to the data, including on relatedness.
In this study, we could not test the significance of association between SCZ PRS and SCZ status for the UK 
Biobank sample because there was no information about SCZ outcome for the sample. However, we conducted 
an association test between the SCZ PRS and bipolar disorder (that is highly correlated with SCZ) for the UK 
Biobank (P-value = 1.02E-08 with 4,508 bipolar cases and 8,821 controls). This showed that the SCZ PRS was 
a reliable predictor of the true underlying SCZ liability for the UK Biobank sample. We also did not adjust for 
the assortative mating effects because the partner information is not available. However, it is not likely that such 
genetic assortative mating effects are substantial although a further study is required to test this hypothesis.
Estimated genetic correlations and their standard errors based on GREML and LDSC were very similar 
(Table S9), but only when the intercept of the LDSC was constrained, which requires the strong assumption of no 
overlapping samples, and only when LD scores were calculated from the actual sample, which is usually not pos-
sible when using GWAS summary statistics. We also observed this phenomenon in our results based on simulated 
data (Supplemental Note 3 and Fig. S9). These observations are in line with the statement in Bulik-Sullivan et al.21 
that standard errors are sacrificed to achieve unbiased genetic correlation and the availability of individual-level 
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genotype data was the most preferable scenario31. Nevertheless, the estimated genetic correlations between SCZ, 
younger AFB and older AFB were consistent using two different approaches, i.e. GREML and LDSC (Table S9).
In summary, this study replicated previously reported evidence for significant genetic overlap between risk of 
SCZ and AFB in women using an independent target sample from the UK Biobank. We further showed that AFB 
in women is genetically heterogeneous (comparing younger to older AFB) and that there is a significant genetic 
correlation between SCZ and AFB. Conducting parallel analyses for AFB in men is of great interest but these 
data are less easily available and AFB has not been recorded for men in the UK Biobank. Our results suggest that 
early, and perhaps also late, age at first birth in women is associated with increased genetic risk for SCZ in the UK 
Biobank samples. These findings contribute new insights into factors contributing to the complex bio-social risk 
architecture underpinning the association between parental age and offspring mental health.
Methods and Materials
Informed consent was obtained from every participant in each study. Research Ethics approval was obtained 
from University of South Australia Human Research Ethics Committee (HREC). All methods were carried out in 
accordance with the relevant guidelines and regulations.
Participants and quality control. Schizophrenia (SCZ) sample. Genome-wide association data were 
available from 18,987 SCZ cases and 22,673 controls from the second phase of the Psychiatric Genomics 
Consortium (PGC)32 with quality control (QC) applied as described in Mehta et al.17. In summary, before 
imputation, PGC group performed a QC for the raw genotypes within each cohort: SNPs with call rate <0.95 
or Hardy-Weinberg equilibrium p-value < 10E-6 in controls or p-value < 10E-10 in cases were excluded. 
Individuals with call rate <0.98 were excluded. Then, the QCed raw genotype data were imputed with IMPUTE2/
SHAPEIT33,34 using the full 1000 Genomes Project dataset35 as the reference set. Post-imputation quality control 
was performed in each cohort as: A best-guess genotype was called if its posterior probability >0.8, otherwise 
treated as missing. SNPs with an imputation r-squared <0.1 or MAF < 0.005, or call rate <0.98 were excluded. 
Out of 39 cohorts, eight cohorts were excluded because the number of SNPs passing the QC process was too small 
and one cohort was excluded because essential covariate information was not available. After the post-imputation 
QC, we combined the genotype data across all cohorts17,32. As in Mehta et al.17, we used HapMap3 SNPs that were 
reliable in estimating (shared) genetic architecture between complex traits36–38. In the combined dataset, SNPs 
with call rate <0.9, individuals with call rate <0.9 were excluded, and one individual in a pair with genomic 
relationship >0.05 was excluded. This less stringent QC for call rate was because SNP and individual QC had 
been already done by the PGC. After this QC, 688,145 SNPs (best-guess genotypes) and 41,630 individuals were 
remained and used to combine with the UK Biobank sample.
UK Biobank sample. In the first version of UK Biobank39 data set, 80,702 female (54,215 with a recode of 
AFB) out of 152,249 genotyped individuals were available from a community sample, in which psychiat-
ric disorders were not enriched, with 72,355,667 imputed SNPs available. Out of all imputed SNPs, 1,242,190 
HapMap3 SNPs were identified, which were filtered through the following QC filtering criteria: SNPs with impu-
tation INFO < 0.617, minor allele frequency (MAF) <0.01, call rate <0.95, and Hardy-Weinberg equilibrium 
P-value < 10–717 were excluded. In addition, ambiguous strand SNPs were excluded. After this QC, 930,841 SNPs 
(best guess genotypes) remained and they were used to merge with the SCZ genotypic data. For individual level 
QC, only Caucasian females were used who clustered within 6 standard deviation from the mean of the EUR 
reference sample40 for the first and second genetic relationship principal components. Individuals were further 
excluded due to call rate <0.95. In addition, one in a pair of individuals was randomly removed if their genomic 
relationship coefficient was more than 0.0517. An important reason for removing closely related individuals was 
to reduce the possibility that the similarity between the phenotypes of those individuals could be caused by 
non-genetic effects (e.g. common environment effects)41. Furthermore, UK Biobank samples were excluded if 
their genomic relationship with any individual in the SCZ or AFB datasets used in Mehta et al.17 was >0.05, in 
order to ensure the independence of the UK Biobank sample. The AFB sample in Mehta et al.17 included 12,247 
genotyped women measured for AFB, who were from four cohorts: Estonia, the Netherlands, Sweden, and the 
United Kingdom. After QC, we used 80,522 individuals (18,957 SCZ cases, 22,673 SCZ controls, and 38,892 UK 
Biobank individuals) and 518,992 SNPs in the main analyses.
Statistical analyses. Estimation of SCZ polygenic risk score (PRS) in UK Biobank sample. We used a GBLUP 
model to generate SCZ PRS for each individual in the UK Biobank sample accounting for the genetic relationship 
between the UK Biobank sample and the SCZ case-control sample. The GBLUP model can be written as
= + +y Xb Zu e,
where y is a vector of phenotypic data (i.e. 1s for SCZ cases, 0s for SCZ controls and missing for UK Biobank 
individuals), b represents vectors of fixed effects including sex, cohort and 20 ancestry principal components 
(PCs)42, u is the vector of SCZ PRS, and e is the vector of residuals. X and Z are design matrices to allocate effects 
to phenotypic data. It is assumed that u is normally distributed as σN G(0, )u
2 , where G is the genomic relation-
ship matrix constructed as described in Yang et al.43 and σu
2 is the additive genetic variance, and e is normally 
distributed as σN I(0, )e
2 , where I is an identify matrix and σe
2 is the residual variance. GBLUP was performed 
using GCTA43 or MTG244,45 so that a subset of u for the UK Biobank sample could be inferred based on the phe-
notypes of the SCZ sample and the genomic relationships between the two data sets. Mean SCZ PRS in the UK 
Biobank individuals grouped by their AFB was estimated to assess the previously reported U-shaped relation-
ship13,17. GBLUP provides more accurate PRS (PRS-GBLUP) under a polygenic genetic architecture than the 
more standard genetic profile score approach18, but for comparison we also calculated PRS by the standard 
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method (PRS-score). To estimate SCZ risk SNP effects, an association test was conducted with PLINK 1.946 using 
the same SCZ GWAS data used in the GBLUP analyses, with phenotypes adjusted for sex, cohort and 20 PCs. 
PRS-scores for individuals in the UK Biobank sample were generated by summing the count of SCZ risk alleles 
weighted by the SNP effects estimated from the association test. In addition to PRS-score, we used the estimated 
SNP effects from the full PGC SCZ GWAS study (33,640 cases and 43,456 controls; publicly available at https://
www.med.unc.edu/pgc/)32 to calculate a further profile risk score in the UK Biobank sample (PRS-scorePGC). 
However, we cannot exclude the possibility of sample overlap or relatedness between the UK Biobank and full 
PGC SCZ data, because we only have a permission to access to the genotypes of 30 cohorts out of 52. Note that we 
used all of the SNPs across the genome (after QC) to calculate SCZ PRS for the UK biobank sample.
Linear prediction. It is of interest to replicate the findings from the epidemiological observation13 that maternal 
ages are associated with SCZ risk in offspring, using the novel design consisting of general community sample 
(UK Biobank) measured for AFB and SCZ PRS. Any significant association between AFB and SCZ PRS from 
a linear prediction gives evidence that the U-shape relationship between maternal ages and risk in offspring 
(observed in McGrath et al.13) can be explained by genetic factors. Using 2,894,688 records from the National 
Danish Registry, McGrath et al.13 reported a U-shaped relationship between risk of SCZ in children and maternal 
age at birth. The resulting equation from the U-shaped relationship (z = 2.7214 − 0.1105X + 0.0018X2) can be 
applied to data of age at first birth of women to generate predictors of risk of SCZ in their children17. We did not 
consider the second model in Mehta et al.17 that was adjusted for partner’s ages because the model was shown 
to be over-corrected17. We calculated the response variable (z) in the UK Biobank sample from the recorded 
age at first birth (X) and this was used as the y-variable in analyses regressing on either PRS-GBLUP, PRS-score 
or PRS-scorePGC and including age at interview, assessment center at which participant consented, genotype 
batch, year of birth and the first 20 PCs as covariates. Socioeconomic status (i.e. education and income level)47 or 
smoking and alcohol drinker status were additionally used to adjust the response variable in sensitivity analyses 
(Fig. S1). Linear models were applied to the group with the full range of AFB records, the subgroup with AFB 
younger than 26 years (<26), and the subgroup with AFB at or older than 26 (≥26), respectively, where the value 
of 26 is the mean of AFB in the UK Biobank sample. From the model, the coefficient of determination (R2) and 
P-value against the null hypothesis (i.e. SCZ PRS of women is not a predictor of AFB) were estimated.
Genomic residual maximum likelihood (GREML). Since previous studies13,17 found that younger and older AFB 
have reciprocal relationship with risk of SCZ (i.e. a U-shaped relationship), it is of interest to test if AFB in women 
is a genetically heterogeneous trait, for instance by estimating the genetic correlation between younger and older 
AFB groups. If the genetic correlation is significantly different from 1, it would imply that the causal variants and/
or their effect sizes differ between younger and older AFB. Moreover, it would be interesting to estimate genetic 
correlations between SCZ case-control data and younger or older AFB groups. The UK Biobank data were divided 
into two groups by younger (<26) and older AFB (≥26). Then, three-variate linear mixed model analysis was 
conducted to estimate genetic variance and covariance between SCZ case-control data, and younger and older 
AFB groups. The model can be written as
= + +
= + + <
= + + ≥
y X b Z g e
y X b Z g e
y X b Z g e
for SCZ sample
for UK Biobank sample with AFB 26
for UK Biobank sample with AFB 26
1 1 1 1 1 1
2 2 2 2 2 2
3 3 3 3 3 3
where y are three column vectors of phenotypic observations (one for each data set or group, i.e. SCZ case-control 
data set, UK Biobank AFB < 26 and UK Biobank AFB ≥ 26). For SCZ case-control data, pre-adjusted pheno-
types corrected for sex, cohort and 20 PCs were used. For the UK Biobank sample, the AFB phenotypes were 
pre-adjusted for sex, age at interview, year of birth, assessment center, genotype batch and 20 PCs. Again, other 
possible confounding factors such as socioeconomic status, and smoking and alcohol drinker status were addi-
tionally controlled in sensitivity analyses to check if the estimates were substantially changed. The GREML anal-
yses were conducted with GCTA43 or MTG244,45 to estimate pairwise genetic correlations among the three data 
sets; SCZ data, and younger AFB and older AFB. We tested if the genetic correlation between SCZ and younger or 
older AFB was significantly different from zero. We also tested if genetic correlation between younger and older 
AFB was significantly different from 1 to assess heterogeneity between the two groups48. We used a Wald test to 
obtain p-values for the test.
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